|
Domestic Patents - Questions You Should Ask Your Patent Attorney
|
|
|
| By
Robert Pershes, J.D.
,
Louis Wagner, J.D.
|
|
|
|
Your research and development team has just shouted "Eureka!" after long and expensive years of research, exclaiming they have developed a next-generation pain reliever. What do you do next? This article explores and suggests your next steps and identifies pertinent questions to ask a patent attorney. The focus is on intellectual property; this article does not address the myriad regulatory issues that must be resolved.
|
|
|
|
Copyrights and Trademarks
|
|
|
| By
Perry J. Viscounty, J.D.
,
Amos E. Hartston, J.D.
,
Heather L. Mayer, J.D.
|
|
|
|
Trademark protection in the US is based on a dual system of federal and state laws.
|
|
|
|
Licensing
|
|
|
| By
Jeff Stewart, J.D.
|
|
|
|
Historically, the big pharmaceutical companies (Big Pharma) have sought to feed their marketing machines by manufacturing blockbuster drugs—chemical-based, one-type-fits-all products that treat chronic conditions such as heart disease or arthritis. This approach has yielded recurring revenue streams from large patient populations. In contrast, biotechnology companies typically have created protein-based drugs,or biologics, to treat acute or niche conditions and diseases. With few exceptions (such as the biotech giant Amgen), biotech companies have foregone doing the marketing and sales of their drugs themselves, and have, instead, relied on others to perform their marketing and sales functions.
|
|
|
|
Intellectual Property Litigation
|
|
|
| By
Gary N. Frischling, J.D.
,
Keith A. Orso, J.D.
|
|
|
|
Patents are litigated in the biopharmaceutical industry perhaps more often than any other form of IP
|
|
|
|
Avoiding Antitrust Issues
|
|
|
| By
Thomas J. Horton, J.D.
|
|
|
|
The Interface of America's Antitrust and Intellectual Property Laws
|
|
|
|
Introduction: An Overview of Intellectual Property
|
|
|
| By
Frederick Brown, J.D.
,
June T. Tai, J.D.
|
|
|
|
Biopharmaceutical companies need to consider intellectual property issues early on, even at the start-up stage.
|
|
|
